---
schema_version: "secwatch.filing_event.v1"
accession: "0001635088-26-000009"
form_type: "8-K"
ticker: "ROIV"
cik: "0001635088"
company_name: "Roivant Sciences Ltd."
filed_at: "2026-02-06T23:59:59+00:00"
generated_at: "2026-05-16T04:06:01.394653+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Roivant reports positive Phase 2 brepocitinib data in CS; Q3 loss $313.7M vs $208.9M

## Summary
- Phase 2 BEACON study: brepocitinib 45mg achieved 22.3-point CSAMI-A improvement vs 0.7 placebo (Δ21.6, p<0.0001).
- NDA submitted to FDA for brepocitinib in dermatomyositis; Phase 3 CS study planned for 2026.
- Q3 loss from continuing ops $313.7M ($0.38/share) vs $208.9M ($0.22); revenue fell to $2M from $9M.
- Cash and marketable securities of $4.5B as of Dec 31, 2025; R&D expenses rose to $165.4M.
- Immunovant's IMVT-1402 D2T RA trial fully enrolled; Genevant jury trial set for Mar 2026.

## SEC filing metadata
- accession: 0001635088-26-000009
- form_type: 8-K
- ticker: ROIV
- cik: 0001635088
- company_name: Roivant Sciences Ltd.
- filed_at: 2026-02-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1635088/000163508826000009/0001635088-26-000009-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1635088/000163508826000009/roiv-20260206.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001635088-26-000009
- JSON: https://secwatch.observer/filing/0001635088-26-000009.json
- Plain text: https://secwatch.observer/filing/0001635088-26-000009.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.